| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advanced colorectal cancer: Which regimes should we recommend?
|
Koehne, C.H.
|
|
|
10 |
8 |
p. 877-882
|
artikel
|
| 2 |
Advanced colorectal cancer: Which regimes should we recommend?
|
C. H. Koehne
|
|
1999
|
10 |
8 |
p. 877-882
6 p.
|
artikel
|
| 3 |
Allelic expression of p73 in human ovarian cancers
|
Codegoni, A.M.
|
|
|
10 |
8 |
p. 949-953
|
artikel
|
| 4 |
Allelic expression of p73 in human ovarian cancers
|
A. M. Codegoni
|
|
1999
|
10 |
8 |
p. 949-953
5 p.
|
artikel
|
| 5 |
Amyloidosis in Hodgkin's and Castleman's diseases
|
Barişta, İ.
|
|
|
10 |
8 |
p. 998-999
|
artikel
|
| 6 |
Amyloidosis in Hodgkins and Castlemans diseases
|
. Barta
|
|
1999
|
10 |
8 |
p. 999-999
1 p.
|
artikel
|
| 7 |
Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization
|
Seong, D.
|
|
|
10 |
8 |
p. 955-959
|
artikel
|
| 8 |
Analysis of Philadelphia chromosome-negative BCRABL-positivechronic myelogenous leukemia by hypermetaphase fluorescence in situhybridization
|
D. Seong
|
|
1999
|
10 |
8 |
p. 955-959
5 p.
|
artikel
|
| 9 |
A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma
|
O'Byrne, K.J.
|
|
|
10 |
8 |
p. 981-983
|
artikel
|
| 10 |
A phase II study of the modulation of 5-fluorouracil and folinic acidwith high-dose infusional hydroxyurea in metastatic colorectal carcinoma
|
K. J. OByrne
|
|
1999
|
10 |
8 |
p. 981-983
3 p.
|
artikel
|
| 11 |
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer
|
Cascinu, S.
|
|
|
10 |
8 |
p. 985-987
|
artikel
|
| 12 |
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil,leucovorin in first-line chemotherapy of metastatic colorectal cancer
|
S. Cascinu
|
|
1999
|
10 |
8 |
p. 985-987
3 p.
|
artikel
|
| 13 |
Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: Impact on the delivery of local-regional radiation therapy
|
Moore, H.C.F.
|
|
|
10 |
8 |
p. 929-936
|
artikel
|
| 14 |
Autologous stem-cell transplant after conventional dose adjuvantchemotherapy for high-risk breast cancer: Impact on the delivery oflocal-regional radiation therapy
|
H. C. F. Moore
|
|
1999
|
10 |
8 |
p. 929-936
8 p.
|
artikel
|
| 15 |
Book review
|
Giaccone, G.
|
|
|
10 |
8 |
p. 874
|
artikel
|
| 16 |
Book review
|
Tattersall, M.
|
|
|
10 |
8 |
p. 1000
|
artikel
|
| 17 |
Communication skills training in oncology: A position paper
|
Kiss, A.
|
|
|
10 |
8 |
p. 899-901
|
artikel
|
| 18 |
Communication skills training in oncology: A position paper
|
A. Kiss
|
|
1999
|
10 |
8 |
p. 899-901
3 p.
|
artikel
|
| 19 |
Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: A phase I study of the Southern Italy Cooperative Oncology Group
|
Comella, P.
|
|
|
10 |
8 |
p. 915-921
|
artikel
|
| 20 |
Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid givenevery other week in the first-line management of advanced colorectalcarcinoma: A phase I study of the Southern Italy Cooperative OncologyGroup
|
P. Comella
|
|
1999
|
10 |
8 |
p. 915-921
7 p.
|
artikel
|
| 21 |
Contents of the next issue
|
|
|
|
10 |
8 |
p. vi
|
artikel
|
| 22 |
Copyright
|
|
|
|
10 |
8 |
p. iv
|
artikel
|
| 23 |
Correlation of the serum concentration of vascular endothelial growth factor (VEGF) and hemoglobin levels in patients with epithelial ovarian cancer
|
Obermair, A.
|
|
|
10 |
8 |
p. 998
|
artikel
|
| 24 |
Correlation of the serum concentration of vascular endothelial growthfactor (VEGF) and hemoglobin levels in patients with epithelial ovarian cancer
|
A. Obermair
|
|
1999
|
10 |
8 |
p. 998-998
1 p.
|
artikel
|
| 25 |
Daily times four vinorelbine plus cisplatin in advanced non-small-cell lung cancer: A phase II trial of a novel schedule
|
Spiridonidis, C.H.
|
|
|
10 |
8 |
p. 989-991
|
artikel
|
| 26 |
Daily times four vinorelbine plus cisplatin in advanced non-small-celllung cancer: A phase II trial of a novel schedule
|
C. H. Spiridonidis
|
|
1999
|
10 |
8 |
p. 989-991
3 p.
|
artikel
|
| 27 |
Editorial Board
|
|
|
|
10 |
8 |
p. v
|
artikel
|
| 28 |
EHA doubles its bets
|
|
|
|
10 |
8 |
p. 867
|
artikel
|
| 29 |
EHA doubles its bets; Lymphoma festival in Lugano; WHO cares aboutcancer?; France hints at less repression; What after Crozemarie?; Too littlecontrol over biological research, say the British; How many breast conferencesdo we need?; Perhaps not everyone knows that...
|
|
|
1999
|
10 |
8 |
p. 867-873
7 p.
|
artikel
|
| 30 |
ESTIC position paper: High-dose chemotherapy for breast cancer, investigation should continue
|
Crown, J.
|
|
|
10 |
8 |
p. 903-905
|
artikel
|
| 31 |
ESTIC position paper: High-dose chemotherapy for breast cancer,investigation should continue
|
J. Crown
|
|
1999
|
10 |
8 |
p. 903-905
3 p.
|
artikel
|
| 32 |
France hints at less repression
|
|
|
|
10 |
8 |
p. 869
|
artikel
|
| 33 |
Hepatitis C infection and B-cell non-Hodgkin's lymphoma in British Columbia: A cross-sectional analysis
|
Shariff, S.
|
|
|
10 |
8 |
p. 961-964
|
artikel
|
| 34 |
Hepatitis C infection and B-cell non-Hodgkins lymphoma in BritishColumbia: A cross-sectional analysis
|
S. Shariff
|
|
1999
|
10 |
8 |
p. 961-964
4 p.
|
artikel
|
| 35 |
How many breast conferences do we need?
|
|
|
|
10 |
8 |
p. 870-871
|
artikel
|
| 36 |
Intensified CHOP in non-Hodgkin's lymphoma: What we know and what we need to know
|
Santoro, A.
|
|
|
10 |
8 |
p. 875-876
|
artikel
|
| 37 |
Intensified CHOP in non-Hodgkins lymphoma: What we know and what we needto know
|
A. Santoro
|
|
1999
|
10 |
8 |
p. 875-876
2 p.
|
artikel
|
| 38 |
In this issue
|
|
|
|
10 |
8 |
p. vi
|
artikel
|
| 39 |
Lymphoma festival in Lugano
|
|
|
|
10 |
8 |
p. 867-868
|
artikel
|
| 40 |
M. A. Kane, P. A. Bunn (eds)., Biology of lung cancer
|
G. Giaccone
|
|
1999
|
10 |
8 |
p. 874-874
1 p.
|
artikel
|
| 41 |
N. Neymark (ed)., Assessing the economic value of anticancertherapies.
|
M. Tattersall
|
|
1999
|
10 |
8 |
p. 1000-1000
1 p.
|
artikel
|
| 42 |
Pathologic and technical considerations in the treatment of ductal carcinoma in situ of the breast with lumpectomy and radiation therapy*
|
Vicini, F.A.
|
|
|
10 |
8 |
p. 883-890
|
artikel
|
| 43 |
Pathologic and technical considerations in the treatment of ductalcarcinoma in situ of the breast with lumpectomy and radiation therapy
|
F. A. Vicini
|
|
1999
|
10 |
8 |
p. 883-890
8 p.
|
artikel
|
| 44 |
Perhaps not everyone knows that…
|
|
|
|
10 |
8 |
p. 871-873
|
artikel
|
| 45 |
Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors
|
Talbot, S.M.
|
|
|
10 |
8 |
p. 907-914
|
artikel
|
| 46 |
Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) anddose intensified cyclophosphamide plus epirubicin in patients withnon-Hodgkins lymphoma and advanced solid tumors
|
S. M. Talbot
|
|
1999
|
10 |
8 |
p. 907-914
8 p.
|
artikel
|
| 47 |
Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: A high-activity, dose-dense weekly regimen for advanced breast cancer
|
Nisticò, C.
|
|
|
10 |
8 |
p. 937-942
|
artikel
|
| 48 |
Phase II study of epirubicin and vinorelbine with granulocytecolony-stimulating factor: A high-activity, dose-dense weekly regimen foradvanced breast cancer
|
C. Nisticò
|
|
1999
|
10 |
8 |
p. 937-942
6 p.
|
artikel
|
| 49 |
Phase I trial of the selective mitochondrial toxin MKT 077 in chemo-resistant solid tumours
|
Propper, D.J.
|
|
|
10 |
8 |
p. 923-927
|
artikel
|
| 50 |
Phase I trial of the selective mitochondrial toxin MKT 077 inchemo-resistant solid tumours
|
D. J. Propper
|
|
1999
|
10 |
8 |
p. 923-927
5 p.
|
artikel
|
| 51 |
Polymyositis with respiratory muscle weakness requiring mechanical ventilation in a patient with metastatic thymoma treated with octreotide
|
Rini, B.I.
|
|
|
10 |
8 |
p. 973-979
|
artikel
|
| 52 |
Polymyositis with respiratory muscle weakness requiring mechanicalventilation in a patient with metastatic thymoma treated with octreotide
|
B. I. Rini
|
|
1999
|
10 |
8 |
p. 973-979
7 p.
|
artikel
|
| 53 |
Primary chemotherapy in operable breast cancer with favorable prognostic factors: A pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN)
|
Nolè, F.
|
|
|
10 |
8 |
p. 993-996
|
artikel
|
| 54 |
Primary chemotherapy in operable breast cancer with favorable prognosticfactors: A pilot study evaluating the efficacy of a regimen with a lowsubjective toxic burden containing vinorelbine, 5-fluorouracil and folinicacid (FLN)
|
F. Nolè,
|
|
1999
|
10 |
8 |
p. 993-996
4 p.
|
artikel
|
| 55 |
Recent advances in the treatment of prostate cancer
|
Kuyu, H.
|
|
|
10 |
8 |
p. 891-898
|
artikel
|
| 56 |
Recent advances in the treatment of prostate cancer
|
H. Kuyu
|
|
1999
|
10 |
8 |
p. 891-898
8 p.
|
artikel
|
| 57 |
Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma
|
Dunsford, M.L.
|
|
|
10 |
8 |
p. 943-947
|
artikel
|
| 58 |
Severe pulmonary toxicity in patients treated with a combination ofdocetaxel and gemcitabine for metastatic transitional cell carcinoma
|
M. L. Dunsford
|
|
1999
|
10 |
8 |
p. 943-947
5 p.
|
artikel
|
| 59 |
Sudden cardio-pulmonary toxicity following a single infusion of gemcitabine
|
Ciotti, R.
|
|
|
10 |
8 |
p. 997
|
artikel
|
| 60 |
Sudden cardio-pulmonary toxicity following a single infusion ofgemcitabine
|
R. Ciotti
|
|
1999
|
10 |
8 |
p. 997-997
1 p.
|
artikel
|
| 61 |
Table of Contents
|
|
|
|
10 |
8 |
p. iii-iv
|
artikel
|
| 62 |
Too little control over biological research, say the British
|
|
|
|
10 |
8 |
p. 870
|
artikel
|
| 63 |
Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo?
|
Wynendaele, W.
|
|
|
10 |
8 |
p. 965-971
|
artikel
|
| 64 |
Vascular endothelial growth factor measured in platelet poor plasmaallows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo?
|
W. Wynendaele
|
|
1999
|
10 |
8 |
p. 965-971
7 p.
|
artikel
|
| 65 |
What after Crozemarie?
|
|
|
|
10 |
8 |
p. 869-870
|
artikel
|
| 66 |
WHO cares about cancer?
|
|
|
|
10 |
8 |
p. 868
|
artikel
|
Tijdschrift beschrijving